Resource impact statement
No significant resource impact is anticipated
Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults. It is recommended for patients with CD30+ peripheral T-cell lymphoma.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the eligible population is expected to be around 100 people per year.
Brentuximab vedotin has a discount that is commercial in confidence. For enquiries about the discount contact: gb.commercial@takeda.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: